CytomX Therapeutics (CTMX) was upgraded by Zacks to a #2 (Buy), signaling rising optimism for future earnings. The note suggests the change could lift the stock in the near term, but it does not cite specific financial figures or guidance changes.
CytomX Therapeutics (CTMX) was upgraded by Zacks to a #2 (Buy), signaling rising optimism for future earnings. The note suggests the change could lift the stock in the near term, but it does not cite specific financial figures or guidance changes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
